Circulatory System

.. her factors include abnormalities in the proteins that regulate blood cell production and a malfunctioning immune system that interferes with the normal blood cell production. Certain environmental factors have been associated with the development of plastic anemia. Chemotherapy drugs such as busulfan or antibiotics such as chloraphenicol can cause temporary or prolonged plastic anemia. Chemicals such as benzene and pesticides, infections such as viral hepatitis and mononucleosis, autoimmune disorders and ionizing radiation also has been linked to the development of plastic anemia.

Although exposure to these agents increases the risk of developing plastic anemia, it is proven that they are not the sole cause of plastic anemia. Plastic anemia was once considered incurable. Today, more than fifty percent of patients diagnosed with plastic anemia can be cured. For patients under the age of fifty and those over fifty that are in good health, the treatment of choice is a bone marrow transplant. However, more than halves of the patients that are diagnosed are ineligible foe a bone marrow transplants because of age or the lack of a suitable bone marrow donor. For these patients, the preferred treatment is immunosuppressive therapy consisting of injections of antithymocyte globulin (ATG), with or without oral closporine. ATG therapy boosts the production of red blood cells, blood cells, and platelets in thirty to fifty percent of patients.

We Will Write a Custom Essay Specifically
For You For Only $13.90/page!

order now

In some cases, blood cell production returns to normal, while in others it returns to a level that allows the patient to have a normal lifestyle. Approximately ten to fifteen percent of patients who initially respond to ATG therapy have the disease relapse during the first twelve months following treatment. Another round of ATG therapy may be administered in an effort to bring blood cell production back to an acceptable level. Some patients who respond to ATG therapy eventually develop another bone marrow disorder such as myelogenous syndrome or acute nonmyelogenous leukemia. These disorders may be temporarily treatable, but are seldom curable. Overall, between thirty and forty percent of patients treated with ATG therapy become long term survivors and the majority of these long term survivors appear to be cured.

Patients who have a relative with matching bone marrow have a seventy to ninety percent chance of being cured following a bone marrow transplant. Patients transplanted with marrow from a related donor whose marrow type nearly matches the patient’s have a fifty- percent chance of being cured. If marrow from a matched unrelated donor is used, the likelihood of a cure is twenty to thirty percent. Physicians determine whether a donor’s marrow type matches the patient’s by examining genetic markers on the surface of white blood cells called HLA antigens. These are the antigens that help the body identify invading organisms, and trigger an immune system attack on any substances that do not belong in that particular person’s body, such as viruses and bacteria. If the patient and donor’s HLA antigens do not match, the patient’s body will perceive the donor’s bone marrow as foreign material to be destroyed.

This condition is called graft rejection and results in a failed bone marrow transplant. The patient’s and the donor’s marrow types must also match to minimize the risk and severity of another complication called graft versus host disease. The primary complication following a bone marrow transplant for plastic anemia is graft versus host disease. In graft versus host, the donor’s bone marrow attacks the patient’s organs and tissues, impairing their ability to function, and increasing the risk of infection. Depending on its severity, graft versus host can be a temporary inconvenience or a life threatening condition.

Graft versus host is often referred to as only one disease, but in reality it is actually two closely related diseases: acute graft versus host disease and chronic graft versus host disease. Patients may develop one, both, or neither. acute graft versus host disease usually occurs within the first three months after the bone marrow transplant. Chronic graft versus host disease usually develops after the third month following the transplant. The earliest sign of acute graft versus host disease is often a skin rash that appears on the hands or feet.

It may spread to other parts of the body, developing into a general redness similar to sunburn, with peeling or blistering skin. Cramping, nausea, and watery or bloody diarrhea are also signs of acute graft versus host disease in the stomach or intestines. Jaundice indicates that graft versus host has affected the liver. Patients with chronic graft versus host disease usually experience skin problems such as a dry, itching rash, a change in skin color, on tautness or tightening of the skin. Occasionally, patients will experience “contractors”, which are the tightening of the tendons in the joints that makes extending or contracting arms and legs difficult. Partial hair loss or premature graying may also occur. Chronic graft versus host may also attack the glands in the body that secrete mucus, saliva and other lubricants.

Patients may experience dry or stinging eyes, a dry mouth or throat, and a burning sensation in the mouth when using toothpaste or eating acidic foods. Chronic graft versus host disease, causing heartburn, stomach pain, or weight loss may affect the digestive tract. It may also affect the liver and lungs, causing wheezing, bronchitis, or pneumonia. To reduce the incidence and severity of acute graft versus host, patients are given immunosuppressive drugs. These drugs are routinely administered for approximately six months after the bone marrow transplant and longer if the patient develops chronic graft versus host disease.

The risk of developing acute graft versus host depends on the source of the bone marrow and the choice of medications given to prevent it. Fifteen to thirty percent of patients transplanted with marrow from a related donor develop acute graft versus host. In most cases, patients develop only a mild or moderate form of the disease. Approximately seventy percent of patients transplanted from an unrelated donor develop the disease. The risk of developing chronic host versus graft depends upon the source of the marrow and the age of the patient. About thirty percent of the patients who receive marrow from a related donor develop the disease.

About seventy percent of the patients who receive marrow from an unrelated donor develop the disease. Although most patients recover from graft versus host disease, symptoms such as skin sensitivity, eye irritation, chronic diarrhea, and less frequently, lung and liver problems or contractors, may persist long term. Most patients, however, do not experience long term debilitating side effects. Some patients transplanted for plastic anemia require a preparative regimen that includes total body irradiation (TBI). Children given TBI have experienced slowed growth and hormone development, and are more likely to be infertile than those whose preparative steps did not include TBI.

Patients of all ages have a greater risk of developing a secondary cancer following TBI than other patients develop. Still, the overall chance of having a secondary cancer is very low. Norma Ramose of the University of Minnesota Hospitals states, “The treatment of severe plastic anemia with bone Marrow transplantation is truly one of modern day medicine’s major success stories”. The treatment for plastic anemia has improved greatly over the past two decades. Prior to 1970, only ten percent of patients lived more than a year after diagnosis.

Now, approximately eighty percent of the patients are alive three to five years after diagnosis. In conclusion, what I have learned is valuable to most and all of my knowledge many of the diseases that I have researched a bout over time is blood related. Jeremy Slaven #21 period 6 table of contents outline Reasearch Bibliography I. Disease :Blood Disease II. types: Anemias, bleeding disorders, lukemias, lymphomas,plasma cell disorders, Myeloproliferative disorders III. Treatment IV.

Research V. bibliagraphy.